Herbert M Pinedo

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi Thrombosis, prevalence and new evidence on current perceptions of risk
    Herbert M Pinedo
    Department of Medical Oncology, Free University of Amsterdam, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Cancer Treat Rev 29:3-5. 2003
  2. ncbi Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells
    H M Pinedo
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Cancer 39:1061-7. 2003
  3. ncbi Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein
    Michelle de Graaf
    Department of Medical Oncology, Division of Gene Therapy, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Hum Gene Ther 15:229-38. 2004
  4. ncbi Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite
    Monique C A Duyndam
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam 1081 HV, The Netherlands
    J Biol Chem 278:6885-95. 2003
  5. ncbi Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo
    Adhiambo M Witlox
    Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:61-7. 2004
  6. ncbi The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer
    Annemarie H van Hattum
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Biochem Pharmacol 64:1267-77. 2002
  7. ncbi Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors
    Tanja D de Gruijl
    Division of Immunotherapy, Department of Medical Oncology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    J Immunol 169:5322-31. 2002
  8. ncbi Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts
    Yvette van Hensbergen
    Department of Medical Oncology, , 1007 MB Amsterdam, The Netherlands
    Clin Cancer Res 10:1180-91. 2004
  9. ncbi A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance
    Tanja D de Gruijl
    Department of Medical Oncology, Division of Immunotherapy, VU University Medical Center, Amsterdam, The Netherlands
    J Immunol 176:7232-42. 2006
  10. ncbi The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro
    Jacques Grill
    Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Ther 6:609-14. 2002

Detail Information

Publications69

  1. ncbi Thrombosis, prevalence and new evidence on current perceptions of risk
    Herbert M Pinedo
    Department of Medical Oncology, Free University of Amsterdam, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Cancer Treat Rev 29:3-5. 2003
    ..Most clinicians treating medical (non-surgical) cancer patients perceived pancreatic tumours to carry a high thrombosis risk in the absence of thromboprophylaxis...
  2. ncbi Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells
    H M Pinedo
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Eur J Cancer 39:1061-7. 2003
    ....
  3. ncbi Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein
    Michelle de Graaf
    Department of Medical Oncology, Division of Gene Therapy, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Hum Gene Ther 15:229-38. 2004
    ..1 days (p < 0.01), while virus alone had no effect. Thus, we have successfully shown that an adenovirus vector encoding a secreted, targeted form of human beta-glucuronidase can further improve DOX-GA3 monotherapy...
  4. ncbi Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite
    Monique C A Duyndam
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam 1081 HV, The Netherlands
    J Biol Chem 278:6885-95. 2003
    ..Altogether, these data suggest that not HIF-1, but rather p38, mediates induction of VEGF mRNA expression by sodium arsenite...
  5. ncbi Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo
    Adhiambo M Witlox
    Department of Orthopedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Clin Cancer Res 10:61-7. 2004
    ..CONCLUSIONS: Targeting adenovirus toward integrins rendered OS cells more sensitive to killing by Ad5-Delta24RGD. These findings suggest that Ad5-Delta24RGD has potential for use in OS treatment...
  6. ncbi The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer
    Annemarie H van Hattum
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Biochem Pharmacol 64:1267-77. 2002
    ..Addition of cisplatin or paclitaxel improved the in vivo antitumor effects of DX-8951f...
  7. ncbi Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors
    Tanja D de Gruijl
    Division of Immunotherapy, Department of Medical Oncology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    J Immunol 169:5322-31. 2002
    ..Because DC targeting in vivo might obviate the need for the in vitro culture of autologous DC for adoptive transfer, CD40-targeted Ad vectors constitute a promising new vaccine modality for tumor immunotherapy...
  8. ncbi Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts
    Yvette van Hensbergen
    Department of Medical Oncology, , 1007 MB Amsterdam, The Netherlands
    Clin Cancer Res 10:1180-91. 2004
    ..Further elucidation of the mechanism of the observed effects of CD13 is warranted to better understand its role in the pathophysiology of ovarian cancer...
  9. ncbi A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance
    Tanja D de Gruijl
    Department of Medical Oncology, Division of Immunotherapy, VU University Medical Center, Amsterdam, The Netherlands
    J Immunol 176:7232-42. 2006
    ....
  10. ncbi The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro
    Jacques Grill
    Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Ther 6:609-14. 2002
    ..We can conclude that organotypic spheroids offer a versatile in vitro system for studying distribution, spread, and oncolysis by adenoviruses in a clinically relevant model...
  11. ncbi Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells
    Hans J J van der Vliet
    Department of Medical Oncology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Cancer Res 63:4101-6. 2003
    ....
  12. ncbi Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2
    Dinja Oosterhoff
    Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, 1007 MB, Amsterdam, The Netherlands
    Mol Cancer Ther 2:765-71. 2003
    ..05). Taken together, these data suggest that OS cells are sensitive for the combination of Ad-sCE2 and CPT-11...
  13. ncbi A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+) Langerhans cell precursor
    Saskia J A M Santegoets
    VU University Medical Center, De Boelelaan 1117, Amsterdam 1081HV, The Netherlands
    J Leukoc Biol 80:1337-44. 2006
    ..We conclude that the MUTZ-3 cell line provides a ready and continuous supply of common myeloid precursors, which should facilitate further study of the ontogeny of myeloid DC lineages...
  14. ncbi Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy
    Martine L M Lamfers
    Department of Neurosurgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Cancer Res 62:5736-42. 2002
    ..These results support further development of Ad5-Delta24RGD in combination with radiation therapy for treatment of these highly malignant tumors...
  15. ncbi A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy
    Michelle de Graaf
    Department of Medical Oncology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
    Biochem Pharmacol 68:2273-81. 2004
    ..This effect may even be more pronounced in man, because of the lower plasma esterase activity than measured in mice...
  16. ncbi MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors
    Allan J Masterson
    Department of Medical Oncology, Division Immunotherapy, VU University Medical Center VUmc, Amsterdam, The Netherlands
    Blood 100:701-3. 2002
    ..These findings demonstrate the unique suitability of MUTZ-3 cells as an unlimited source of CD34+ DC progenitors for the study of cytokine-induced DC differentiation...
  17. ncbi O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells
    Dennis Fontijn
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Mol Cancer Ther 6:2807-15. 2007
    ..There were no changes in sensitivity to docetaxel and doxorubicin. In conclusion, bFGF overexpression can result in resistance against temozolomide mediated by demethylation of the O6-methylguanine-DNA-methyltransferase promoter...
  18. ncbi The immunoregulatory role of CD1d-restricted natural killer T cells in disease
    Hans J J van der Vliet
    The Departments of Pathology, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands
    Clin Immunol 112:8-23. 2004
    ..Here, we review the immunoregulatory role of NKT cells in disease and discuss NKT cell based immunotherapeutic strategies...
  19. ncbi 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer
    Jacobus J M van Der Hoeven
    Departments of Nuclear Medicine and PET Research, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    J Clin Oncol 22:1253-9. 2004
    ..To prospectively evaluate the effect of adding whole-body (18)F-2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) to conventional screening for distant metastases in patients with locally advanced breast cancer (LABC)...
  20. ncbi Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer
    Robert Mauritz
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Clin Colorectal Cancer 8:146-54. 2009
    ....
  21. ncbi Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo
    Robert Mauritz
    Department of Medical Oncology, VU University Medical Center, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 62:937-48. 2008
    ..Collectively, this study underscores that modulation of dietary folate status can provide a basis within which the therapeutic effect of antifolates may be further improved...
  22. ncbi Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts
    Fransien de Boer
    Department of Hematology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    J Hematother Stem Cell Res 11:951-63. 2002
    ..Further development of this assay should allow its incorporation into the routine CD34(+) assessment of post-thawed samples in clinical flow cytometry laboratories...
  23. ncbi Gene therapy for meningioma: improved gene delivery with targeted adenoviruses
    Clemens M F Dirven
    Department of Neurosurgery, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Neurosurg 97:441-9. 2002
    ..Gene therapy is an emerging strategy for the treatment of brain tumors, which the authors investigated to determine whether adenoviruses could be used for gene transfer in meningioma cells...
  24. ncbi A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors
    Giuseppe Giaccone
    Department of Medical Oncology, Vrije Universiteit Medical Center, HV 1081 Amsterdam, The Netherlands
    Clin Cancer Res 8:3702-9. 2002
    ..We performed a dose escalation study of KRN7000 in advanced cancer patients...
  25. ncbi Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells
    Monique C A Duyndam
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Biochem Pharmacol 74:191-201. 2007
    ..This knowledge may be useful for future treatment schedules including agents that target the HIF-1 signalling pathway...
  26. ncbi The 18 kDa isoform of basic fibroblast growth factor is sufficient to stimulate human melanoma growth and angiogenesis
    Dennis Fontijn
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Melanoma Res 17:155-68. 2007
    ..Taken together, overexpression of the 18 kDa basic fibroblast growth factor protein only can promote autocrine melanoma cell growth and paracrine-driven angiogenesis...
  27. ncbi Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer
    Rutger Middelburg
    Department of Medical Oncology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Clin Cancer Res 11:1863-9. 2005
    ..Because PUMA is a known member of the family of BH3-only proapoptotic proteins, this finding suggests PUMA's potential importance for the response to anticancer drugs...
  28. ncbi Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma
    Reinhard Bos
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Cancer 97:1573-81. 2003
    ..Therefore, the use of immunohistochemical assessment of HIF-1alpha as a new predictor of poor outcome may improve clinical decision-making regarding adjuvant treatment of patients with lymph node negative breast carcinoma...
  29. ncbi Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha)
    Reinhard Bos
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Oncogene 22:8948-51. 2003
    ..The cases with amplification in BCL-6 showed an increased (25%) incidence of BCL-6 protein overexpression. Thus, this study is the first to show that BCL-6 oncogene activation plays a role in cancers other than lymphomas...
  30. ncbi Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells
    Michiel de Bruin
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Mol Pharmacol 66:1054-60. 2004
    ..However, this may also negatively affect capecitabine efficacy...
  31. ncbi Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer
    Robert Mauritz
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Int J Cancer 120:2609-12. 2007
    ..2-fold lower than in 18 primary tumors of unexposed patients (p = 0.027). In conclusion, administration of 5FU in vivo influences the gene expression of TS and DPD...
  32. ncbi Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines
    Godefridus J Peters
    Department of Medical Oncology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Int J Oncol 28:237-44. 2006
    ..6-fold directly after exposure but did not clearly affect the AUA0-25 h. In conclusion, dFdC can affect both Pt-DNA adduct formation and repair, depending on the initial sensitivity of the cells...
  33. ncbi Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored
    Jan Buter
    Department of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Curr Oncol Rep 5:171-6. 2003
  34. ncbi Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency
    Victor W van Beusechem
    Division of Gene Therapy, Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Cancer Res 62:6165-71. 2002
    ..CRAd potency was increased up to >100-fold by p53 expression. We conclude that CRAds expressing p53 are promising new agents for more effective treatment of many human cancers...
  35. ncbi Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines
    Tanja D de Gruijl
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Cancer Immunol Immunother 57:1569-77. 2008
    ....
  36. ncbi Cytosolic beta-glycosidases for activation of glycoside prodrugs of daunorubicin
    Michelle de Graaf
    Department of Medical Oncology, Vrije Universiteit Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
    Biochem Pharmacol 65:1875-81. 2003
    ....
  37. ncbi Simulation model of doxorubicin activity in islets of human breast cancer cells
    Jan Lankelma
    Department of Medical Oncology, VU Medical Center, Room BR232, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Biochim Biophys Acta 1622:169-78. 2003
    ..In the model doxorubicin exposure resulted in less cell damage inside the tumor islets than at the rim...
  38. ncbi Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity
    Judith R Kroep
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Mol Cancer Ther 1:371-6. 2002
    ..In conclusion, the clear correlation between dCK levels and gemcitabine sensitivity in various murine tumors and human tumor xenografts may be a prognostic parameter when considering gemcitabine therapy...
  39. ncbi Beta-glucuronidase-mediated drug release
    Michelle de Graaf
    Department of Medical Oncology, Division of Gene Therapy, Vrije Universiteit Medical Centre, P.O. Box 7057, Amsterdam, 1007 MB, The Netherlands
    Curr Pharm Des 8:1391-403. 2002
    ..Enhancement of the therapeutic effects of glucuronide prodrugs, also in patients with small tumour lesions, may possibly be achieved by techniques that target beta-glucuronidase specifically to the site of the tumour...
  40. ncbi Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance
    Annemarie H van Hattum
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Int J Cancer 100:22-9. 2002
    ..In contrast to topotecan, BNP1350 proved not to be a good substrate for BCRP. Overall, we conclude that BNP1350 offers advantages over topotecan expressed by high efficacy in experimental human ovarian cancer and poor affinity for BCRP...
  41. ncbi Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies
    Bart C Kuenen
    Department of Medical Oncology, VU Medical Center, Amsterdam, Netherlands
    Clin Cancer Res 11:6240-6. 2005
    ..CONCLUSIONS: The maximum tolerated dose of SU6668 given orally, thrice daily under fed conditions, is 100 mg/m2. Because of the low plasma levels reached at this dose level, the efficacy of SU6668 as a single agent is not to be expected...
  42. ncbi Homing and clonogenic outgrowth of CD34(+) peripheral blood stem cells: a role for L-selectin?
    Fransien de Boer
    Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
    Exp Hematol 30:590-7. 2002
    ..In the present study, we determined the role of L-selectin in different engraftment steps, i.e., adhesion to endothelial cells, migration, and clonogenic outgrowth by in vitro assays that closely mimic the in vivo situation...
  43. ncbi Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid
    Yvette van Hensbergen
    Vrye Universiteit Medical Center, Department of Medical Oncology, 1081 HV Amsterdam, The Netherlands
    Clin Cancer Res 8:3747-54. 2002
    ..If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium...
  44. ncbi On our way to targeted therapy for cachexia in cancer?
    Manon S A Boddaert
    Department of Medical Oncology, VUMC Cancer Center Amsterdam, Amsterdam, The Netherlands
    Curr Opin Oncol 18:335-40. 2006
    ..Despite extensive research in an attempt to better understand the mechanisms involved, progress in the management of cancer cachexia has been slow...
  45. ncbi Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods
    Judith R Kroep
    Department of Medical Oncology, Amsterdam, The Netherlands
    Mol Imaging Biol 5:337-46. 2003
    ..CONCLUSIONS: FDG-PET reliably predicted response in LAGEC. FDG-PET measurements using Patlak analysis or the more clinical applicable SKM and SUV-BW were acceptable alternatives to NLR...
  46. ncbi Making use of the primary tumour
    Arnold Baars
    Department of Medical Oncology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Bioessays 25:79-86. 2003
    ....
  47. ncbi Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation
    Claudia C Sombroek
    Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Immunol 168:4333-43. 2002
    ..In conclusion, this study demonstrates that primary tumors negatively impact DC development and function through COX-1 and -2 regulated factors, whereas tumor-derived cell lines may lose this ability upon in vitro propagation...
  48. ncbi The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase
    Michiel de Bruin
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, P.O. Box 7057, 1081 HV Amsterdam, The Netherlands
    Eur J Pharmacol 491:93-9. 2004
    ..This demonstrated that regulation is drug and cell line dependent...
  49. ncbi Natural Killer T cells
    Hans J J van der Vliet
    Lancet Oncol 3:574. 2002
  50. ncbi Expression of scFvs and scFv fusion proteins in eukaryotic cells
    Michelle de Graaf
    Division of Gene Therapy, Department of Medical Oncology, Vrije University, Amsterdam, The Netherlands
    Methods Mol Biol 178:379-87. 2002
  51. ncbi Molecular tests for colorectal cancer screening
    Linda J W Bosch
    Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Colorectal Cancer 10:8-23. 2011
    ..Evaluation in large well-controlled randomized trials is the next step needed to take molecular markers for CRC screening to the next level and warrant implementation in a screening setting...
  52. ncbi Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts
    Monique C A Duyndam
    Department of Medical Oncology, Vrije Universiteit Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Am J Pathol 160:537-48. 2002
    ..These data provide functional evidence for a role of VEGF(165) in cyst formation and monocyte/macrophage infiltration...
  53. ncbi Immunologic and biologic properties of the primary tumor during prolonged neoadjuvant chemoimmunotherapy
    Evelien Bodar
    Department of Medical Oncology, VU Medical Centre, Amsterdam, The Netherlands
    Oncology (Williston Park) 16:32-9. 2002
    ..Aside from investigations concerning the immune system, other biologic processes, such as tumor angiogenesis, are being investigated at the same time...
  54. ncbi Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel
    Geertruida M Kolfschoten
    Department of Medical Oncology, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    Biochem Pharmacol 63:733-43. 2002
    ..We conclude that docetaxel is able to activate caspase-3, induce Bcl-2 phosphorylation and apoptosis in cells that show a prolonged G2/M arrest, but cells may also die by a caspase-3-independent cell death mechanism...
  55. ncbi The role of VEGF in oncology: effects on hemostasis and thrombosis
    Herbert M Pinedo
    Department of Medical Oncology, VUMC, Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 33:11-2. 2003
  56. ncbi A doxorubicin-CNGRC-peptide conjugate with prodrug properties
    Yvette van Hensbergen
    Department of Medical Oncology, Vrije Universiteit Medical Centre, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands
    Biochem Pharmacol 63:897-908. 2002
    ..More research is needed to identify the optimal specific chemical configuration of DOX-peptide conjugates for in vivo targeting and receptor-mediated cellular uptake...
  57. ncbi Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine)
    Andries M Bergman
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Drug Resist Updat 5:19-33. 2002
    ..However, the only strong correlations with gemcitabine sensitivity are dCK activity and dFdCTP pools, with a potential important role for ribonucleotide reductase...
  58. ncbi Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished
    Victor W van Beusechem
    Division of Gene Therapy, Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    J Virol 76:2753-62. 2002
    ..Hence, single-chain targeted doubly ablated adenoviral vectors are promising tools for cancer gene therapy. They should provide an improved therapeutic index with efficient tumor transduction and effective protection of normal tissue...
  59. ncbi Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis
    Robert Mauritz
    Department of Medical Oncology, VU Medical Center, Amsterdam, The Netherlands
    Biochem Pharmacol 63:105-15. 2002
    ....
  60. ncbi Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection
    Hans J J van der Vliet
    Department of Medical Oncology, Pathology, and Internal Medicine, Free University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Immunol 168:1490-5. 2002
    ..In this longitudinal study no evidence was found to support an important role of Valpha24+Vbeta11+ NKT cells in determining the rate of progression during HIV-1 infection...
  61. ncbi Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug
    Franciscus M H de Groot
    Department of Organic Chemistry, NSR Center for Molecular Structure, Design and Synthesis, University of Nijmegen, 6525 ED Nijmegen, The Netherlands
    Mol Cancer Ther 1:901-11. 2002
    ..On the basis of these in vitro results, derivatives of 1 with improved water solubility are considered good candidates for additional development and in vivo evaluation of this dual targeting concept...
  62. ncbi Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors
    Bart C Kuenen
    Departments of Medical Oncology and Pulmonology, Vrije Universiteit Medical Center
    J Clin Oncol 20:1657-67. 2002
    ..CONCLUSION: The incidence of thromboembolic events, possibly related to the particular regimen tested in this study, discourages further investigation of this regimen...
  63. ncbi Inhibition of angiogenesis in cancer patients
    Henk M W Verheul
    Dept of Internal Medicine, University Medical Center, Utrecht, The Netherlands
    Expert Opin Emerg Drugs 10:403-12. 2005
    ..In combination with chemotherapy, other serious side effects, such as bleeding and thrombosis, also occur. Here, the preclinical and clinical data of antiangiogenic agents in clinical trials at this moment are summarised...
  64. ncbi Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
    Byeong Ho Park
    Dong A University College of Medicine, Busan, South Korea
    Lancet Oncol 9:533-42. 2008
    ..We aimed to assess intratumoral injection of JX-594 in patients with refractory primary or metastatic liver cancer...
  65. ncbi High-dose 5-Fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-Fluorouracil incorporation into RNA in murine tumors
    Giovanni Codacci-Pisanelli
    Department of Internal Medicine, University La Sapienza, Rome, Italy
    Oncology 62:363-70. 2002
    ..Since preliminary results indicate that UDPG is well tolerated by patients, the use of higher 5FU doses may improve the response rate of human tumors...
  66. ncbi The importance of platelet counts and their contents in cancer
    Henk M W Verheul
    Clin Cancer Res 9:3219-21. 2003
  67. ncbi Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
    Henk M W Verheul
    University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
    Nat Rev Cancer 7:475-85. 2007
    ..In addition, understanding the molecular mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed...